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Role of tumor necrosis factor
superfamily in neuroinflammation
and autoimmunity
Sandip Sonar and Girdhari Lal*
National Centre for Cell Science, Pune, India
Tumor necrosis factor superfamily (TNFSF) molecules play an important role in the activa-
tion, proliferation, differentiation, and migration of immune cells into the central nervous
system (CNS). Several TNF superfamily molecules are known to control alloimmunity,
autoimmunity, and immunity. Development of transgenic and gene knockout animals, and
monoclonal antibodies against TNFSF molecules have increased our understanding of
individual receptor–ligand interactions, and their intracellular signaling during homeostasis
and neuroinflammation. A strong clinical association has been observed between TNFSF
members and CNS autoimmunity such as multiple sclerosis and also in its animal model
experimental autoimmune encephalomyelitis. Therefore, they are promising targets for
alternative therapeutic options to control autoimmunity. Although, TNFSF ligands are
widely distributed and have diverse functions, we have restricted the discussions in
this review to TNFSF receptor–ligand interactions and their role in the pathogenesis of
neuroinflammation and CNS autoimmunity.
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Introduction
CD4+ T cells are one of the key adaptive immune cells that play an important role in several autoim-
mune diseases like multiple sclerosis (MS), experimental autoimmune encephalomyelitis (EAE),
inflammatory bowel disease (IBD), and collagen-induced arthritis (CIA). Interactions between
tumor necrosis factor superfamily (TNFSF) ligands and TNF receptor superfamily (TNFRSF) recep-
tors provide the costimulatory signals that control the survival, proliferation, differentiation, and
effector function of immune cells. Therefore, signaling from these ligand–receptor pairs effectively
Abbreviations: APC, antigen-presenting cells; APRIL, a proliferation-inducing ligand; BAFF, B-cell activating factor; BBB,
blood–brain barrier; BCMA, B-cell maturation factor; CNS, central nervous system; CTLA-4, cytotoxic T-lymphocyte-
associated protein-4; DR, death domain containing receptor; EAE, experimental autoimmune encephalomyelitis; GA, glati-
ramer acetate; GITR, glucocorticoid-induced TNFR family-related gene; GITRL, glucocorticoid-induced TNFR family-
related gene ligand; gld, generalized lymphoproliferative disease; GM-CSF, granulocyte–macrophage colony-stimulating factor;
HEVM, herpes virus entry mediator; ICAM-1, intercellular adhesion molecule-1; LIGHT, homologous to lymphotoxins,
exhibits inducible expression, and competes with HSV glycoprotein D for herpesvirus entry mediator (HVEM), a receptor
expressed by T lymphocytes; lpr, lymphoproliferative; LTα, lymphotoxin alpha; LTβR, lymphotoxin receptor beta; MMP,
matrix metallopeptidase; MOG, myelin oligodendrocyte glycoprotein; MS, multiple sclerosis; RANK, receptor activator of
NF-κB; RANKL, receptor activator of NF-κB ligand; TACE, TNF alpha converting enzyme; TACI, transmembrane activator,
calcium modulator, and cyclophilin ligand interactor; TNF, tumor necrosis factor; TNFR, TNF receptor; TNFRSF, TNF
receptor superfamily; TNFSF, TNF superfamily; TRAF, TNF receptor-associated factor; TRAIL, TNF-related apoptosis-
inducing ligand; TRAILR,TNF-related apoptosis-inducing ligand receptor; Treg, regulatoryCD4Tcells; TWEAK,TNF-related
weak inducer of apoptosis; VCAM-1, vascular cell adhesion molecule-1; VEGI, vascular endothelial cell-growth inhibitor.
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helps in maintaining immune cell homeostasis and in regulating
the pathology of autoimmune diseases (1–4).
About 19 TNFSF ligands have been identified, which include
TNF-α, TNF-β [also known as lymphotoxin alpha (LTα)],
lymphotoxin-β (LT-β), CD27L, CD30L, CD40L, FasL, 4-1BBL,
OX40L, TNF-related apoptosis-inducing ligand (TRAIL), LIGHT
(homologous to lymphotoxins, exhibits inducible expression,
and competes with HSV glycoprotein D for herpesvirus entry
mediator (HVEM), a receptor expressed by T lymphocytes),
receptor activator of NF-κB ligand (RANKL), TNF-related weak
inducer of apoptosis (TWEAK), a proliferation-inducing ligand
(APRIL), B-cell activating factor (BAFF), vascular endothelial
cell-growth inhibitor (VEGI), ectodysplasin A (EDA-A1, EDA-
A2), and glucocorticoid-induced TNFR family-related gene
ligand (GITRL) (Figure 1). While expressions of TNFSF ligands
are induced largely on professional antigen-presenting cells
(APCs; dendritic cells, B cells, macrophages), their expression
is also reported on T cells, NK cells, mast cells, eosinophils,
basophils, endothelial cells, thymic epithelial cells, and smooth
muscle cells (5).
FIGURE 1 | Interaction of TNF superfamily ligand and its receptors. The
vertical dotted lines represent the cytoplasmic membrane where receptors or
ligands are attached. The horizontal dotted line shows the receptor and its
cognate ligand interaction.
TNF receptor superfamily members are transmembrane pro-
teins having cysteine-rich motifs in their extracellular domains
that bind to their cognate ligands (Figure 1). About 30members of
TNFRSF have been identified (3, 6, 7). Depending upon the spe-
cific intracellular signal induced by TNFRSF members, they can
be categorized into three groups – death domain (DD)-containing
receptors, decoy receptors, and TNF receptor-associated factor
(TRAF)-binding receptors (8). Some TNFRSFs such as TNFR-1,
Fas, DR3, DR4, DR5, and DR6, contain their own DDs. How-
ever, they also interact with other cytoplasmic DD-containing
adaptor molecules (9). This receptor–adaptor complex acts as
a scaffold for binding of immature pro-caspase, which then
undergoes auto-cleavage, leading to the formation of the death-
inducing signaling complex (DISC) and induction of apoptosis
(9, 10). Some other TNFRSFs, such as TNFR-2, CD27, CD30,
CD40, glucocorticoid-induced TNFR family-related gene (GITR),
Fn1, lymphotoxin beta-receptor (LTβR), OX40, receptor activa-
tor of NF-κB (RANK), and XEDAR, lack a DD and contain
motifs with four to six amino acids called TRAF-interacting
motifs (TIMs) which recruits TRAF proteins. TRAF proteins are
adaptor molecules that activate multiple downstream signaling
pathways such as NF-κB, Janus kinase (JNK), ERK, p38MAPK,
and PI3K that help in cell survival, proliferation, and cytokine
production (11).
There are at least five anti-TNFmedications (Etanercept, Inflix-
imab, Adalimumab, Golimumab, and Certolizumab) approved
by the U.S. Food and Drug Administration (FDA) for the treat-
ment of rheumatoid arthritis (RA). Most of these biologics
bind to soluble TNF molecules and prevent their binding to
TNF-receptors. This blocks the production of pro-inflammatory
cytokines such as IL-1, IL-6, or IFN-γ. Anti-TNF antibodies can
also bind to surface-expressed TNF molecules and induce reverse
signaling or antibody-induced cell death (AICD) (12, 13). In
this review, we discuss the role of TNFSF–TNFRSF members
that play a role in neuronal inflammation, the possible molecu-
lar mechanisms involved, and the efficiency of these molecules
in controlling central nervous system (CNS) inflammation and
autoimmunity.
The CNS is considered as an immune-privileged site and con-
sists of a network of CNS microvessels. These microvessels are
formed by a highly specialized endothelial lining supported by
astrocytes, pericytes,microglial cells, and neurons, which together
form a very firm blood–brain barrier (BBB). The BBB restricts
entry of immune cells into the CNS, thereby actively maintain-
ing a homeostasis. However, under inflammatory conditions,
the BBB gets disrupted and immune cells migrate into the CNS
parenchyma. A disrupted BBB is one of the hallmarks of autoim-
mune demyelinating diseases like MS and EAE (14–16).
Watts et al. have reported that vascular endothelial growth
factor receptor (VEGFR) signaling activates JNK and posi-
tively regulates the angiogenesis and barrier property of BBB
endothelial cells (17). They also reported that death receptor
6 (TNFRSF21) and TROY (TNFRSF19) were regulated in the
acquisition and development of barrier property in BBB (17).
Both these TNFRSF members are downstream targets of the
Wnt/beta-catenin signaling pathway in the BBB endothelial cells.
Dysregulation of TNFRSF21/TNFRSF19 signaling leads to the
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TABLE 1 | TNF superfamily in neuroinflammation.
TNFSF receptor TNFSF ligand Blocking/genetic deficiency/over-expression Effect on neuroinflammation in EAE or MS Reference
TNFR-1 and
TNFR-2
TNFα Anti-TNFα or TNFR-1-IgG Reduced demyelination but CNS infiltration is
unaffected in EAE
(22)
TNFα /  Severe EAE (25, 26)
Neuron-specific TNF transgenic mice Spontaneous EAE (27)
TNFR-1/2 /  Mild EAE (30)
TNFR-2 /  Hyper susceptible to EAE (30)
OX40 OX40L Anti-OX40 Substantial inhibition of EAE (81)
OX40-Ig Mild EAE (82)
Anti-OX40L Reduced infiltration in spinal cord in both active
and passive EAE
(84)
OX40L /  Controls active EAE, but do not have effect on
passive EAE
(138)
4-1BB 4-1BBL Agonistic anti-4-1BB (2A) Reduced incidence and severity of EAE. It also
prevents the relapse of EAE
(87)
4-1BBL /  Controls EAE by reducing VCAM-1 expression on
spinal cord endothelial vessels
(89)
GITR GITRL GITRL blocked by anti-GITRL antibody on B cells Severe passive EAE (100)
DR4/DR5 TRAIL Recombinant soluble TRAIL Delayed onset and mild EAE (102)
Anti-TRAIL antibody Severe EAE (102)
TRAIL /  Hypersusceptibility to EAE (102)
Fn14 TWEAK TWEAK transgenic mice Hypersusceptibility to EAE (109)
Recombinant soluble TWEAK Severe demyelination (110)
Anti-TWEAK Mild EAE (116)
Fn–TRAIL fusion protein Delayed onset and mild EAE (118)
CD40 CD40L Anti-CD40L Prevents relapse when administered at acute
phase of relapsing–remitting EAE
(137)
Substantial inhibition of EAE (135)
CD40L /  Prevents EAE (136)
CD40 /  Protects from EAE (138–140)
Fas FasL Fas /  or FasL /  Resistant to EAE (39, 40)
Fas (Ipr) and FasL (gld) mutant mice Spontaneous EAE (37, 38)
Recombinant FasL Reduces the incidence and severity of EAE (41, 42)
Astrocyte-specific FasL /  Reduces the severity of EAE (45)
CD27 CD70 Anti-CD70 Suppresses EAE (121)
CD70 /  or CD27 /  Severe EAE (124)
CD70-transgenic mice Reduced demyelination and mild EAE (125)
MOG35–55-specific TCR transgenic mice
overexpressing CD70 in B cells (2D2CD70 Tg)
Increases the incidence and severity of
spontaneous as well as MOG35–55-induced EAE
(126)
BAFF-R BAFF BAFF-R /  Exacerbation of EAE (57)
Soluble human BCMA-Fc Delays the onset and reduces the severity of
human recombinant MOG (MOG1–121)-induced
EAE in C57BL/6 mice
(59)
Anti-BLys (Anti-BAFF) Attenuated EAE in marmoset monkeys (61)
LTβR LTα LTβR–Ig fusion protein Mild EAE (128)
LTα /  or LTβ /  Mild EAE (130)
HVEM LIGHT, LTα,
BTLA, and CD160
LIGHT /  Severe EAE with high mortality (131)
HVEM /  Hyper-susceptibility to EAE (141)
disruption of endothelial BBB. Since Wnt/beta-catenin signaling
is required for CNS angiogenesis but not for peripheral vascu-
lature (18, 19), an understanding of the molecular mechanism
of this signaling would help in designing novel therapeutics or
biologics that target TNFSF–TNFRSF interactions, to control CNS
autoimmunity.
The importance of TNF superfamily receptors and ligands in
neuroinflammation are listed in Table 1. Some of the recep-
tor–ligand interactions and their function at BBB (Figure 2)
and in the brain parenchyma (Figure 3) are depicted. The role
of important TNFSF–TNFRSF pairs in neuroinflammation and
autoimmunity are discussed in details below.
TNFR–TNFa
Tumor necrosis factor alpha (TNFα or TNFSF2) is a
homotrimeric transmembrane protein that plays an important
role in systemic inflammation. TNFα is expressed as amembrane-
bound precursor (tmTNFα), which is later cleaved between
Ala76–Val77 by a metalloproteinase known as TNFα-converting
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FIGURE 2 | TNFSF receptor–ligand interaction at endothelial BBB during
neuroinflammation. BBB endothelial cells express TNFSF receptors during
inflammatory condition, and interact with the TNFSF ligand in soluble form as
well as on infiltrating immune cells. (I) Inflamed BBB endothelial cells express
CD40. Interaction of CD40 with CD40L-expressing activated immune cells leads
to up-regulation of adhesion molecules and chemokine secretion by BBB
endothelial cells. This promotes the migration of pathogenic immune cell
subsets into the CNS parenchyma. (II) OX40 expression can be induced in BBB
endothelial cells during inflammation, which facilitates the migration of OX40L+
immune cells across the BBB. (III) Under inflammatory conditions, BBB
endothelial cells up-regulate TNFR-1, which bind to soluble TNF secreted from
various immune cells, such as activated Th1 cells, B cells, macrophages, and
NK cells. Binding of TNF with TNFR-1 increases the paracellular permeability of
BBB endothelial vessels. (IV) Inflamed BBB endothelial cells express Fn14 that
binds to soluble TWEAK molecules. This leads to the up-regulation of cytokines,
chemokines, cell adhesion molecules, and matrix metalloprotenase-9 (MMP-9).
Increased expression of CCL2 and ICAM-1 facilitates the migration of
pathogenic immune cells; whereas MMP-9 helps in the degradation of laminin
molecules present in the basement membrane, resulting in loosening of
the BBB.
enzyme (TACE), and released as soluble TNFα (sTNFα). TNFα
is produced by many cell types, including activated macrophages,
dendritic cells, monocytes, NK cells, CD4+ T cells, CD8+ T
cells, astrocytes, and microglia (20). TNFα interacts with two
receptors; TNF receptor type-1 (TNFR-1, also known as CD120a,
p55/60) and TNF receptor type-2 (TNFR-2, also known as
CD120b, p75/80). Low and constitutive expression of TNFR-1
is found on almost all nucleated cells, and can be activated by
both membrane-bound TNFα (tmTNFα) and sTNFα. However,
expression of TNFR-2 is inducible and restricted to myeloid and
lymphoid lineages. TNFα acts as a pro-inflammatory cytokine
during the early phase of EAE, but shows immunosuppressive
properties in the later phase. To be biologically functional,
tmTNFα and sTNFα monomers must form homodimers.
While both tmTNFα and sTNFα can bind to TNFR-1, sTNFα
interacts with higher affinity than TNFR-2, leading to an
inflammatory response. The tmTNFα mainly interacts with
TNFR-2 and promotes cell survival (21). Blocking of TNFα by
the administration of a soluble TNFR-1–IgG fusion protein or
neutralization of anti-TNFα antibody has been shown to control
the development of EAE (22). Interestingly, these biologics
prevented demyelination but did not control the infiltration of
immune cells into the CNS (22). Furthermore, such regimens
also reduced the activation of CD4+ T cell and microglia cells,
and prevented demyelination in CNS (23, 24). While Korner
et al. reported that a deficiency of TNFα only delays the disease
progression and resulted in disease of comparable severity (25),
others have reported that TNFα-deficient mice developed a more
severe myelin oligodendrocyte glycoprotein (MOG) peptide-
induced EAE as compared to wild-type littermate controls (26).
Expression of TNFα, specifically in neurons in the transgenic
mice led to the development of spontaneous inflammatory
demyelination (27). It has been reported that deficiency of TNFα,
LT-α, and TNFR-1 or neutralization of TNF-α and LTα with
monoclonal antibodies greatly reduced the severity of EAE
(28–30). In contrast, TNFR-2-deficient mice developed more
severe inflammation and demyelination in MOG35–55-induced
EAE (30). Specific expression of tmTNFα in the transgenic mice
showed reduced initiation and severity of the EAE, suggesting
that selective targeting of sTNFα/TNFR-1 signaling may be
helpful in controlling CNS autoimmunity.
In MS patients, TNFα were found to be expressed at very
high levels in the CNS lesions and cerebrospinal fluids, but
not in serum (23, 24), suggesting that TNFα was produced
locally in the inflamed CNS. This indicates that TNFα might
be a good target for therapy against MS. However, while TNFα
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FIGURE 3 | TNFSF receptor–ligand interaction in the CNS
parenchyma during neuroinflammation. TNFSF receptors and ligands
are expressed on both CNS infiltrating effector immune cells and
CNS-resident cells. The interaction of this receptor–ligand greatly influences
the outcome of neuroinflammatory disease like multiple sclerosis and EAE. (I)
Both neurons and oligodendrocytes express functional DR5 in the CNS
during EAE. DR5 on the neurons as well as on oligodendrocytes interacts
with TRAIL molecules present on either microglial cells or infiltrating immune
cells, leading to apoptosis of DR5-expressing cells. (II) Activated astrocytes
and microglial cells up-regulate FasL expression on their surface. The
interaction of FasL with Fas-expressing cells leads to apoptosis and
elimination of pathogenic effector immune cells. (III) Neuronal cells express
TNF and that can interact with TNFR-1 present on various CNS-resident
cells, such as astrocytes, microglial cells, and oligodendrocytes. Interactions
of TNF with TNFR-1-expressing cells lead to apoptosis of TNFR-1+ cells.
(IV) Mast cells are known to localize close to the astrocytes during EAE in the
brain. CD40L present on mast cells interact with CD40-expressing
astrocytes, which induces increased production of inflammatory cytokines
and chemokines. Local production of inflammatory molecules can augment
inflammation and tissue damage in the CNS.
inhibitors showed protection in the mouse model of EAE, adverse
effects were observed during clinical trials in MS patients (21).
Similarly, a clinical trial with TNFR-1 fusion protein in MS
patients showed disease exacerbation, and the trial was stopped
(31). This increased demyelination with TNFα antagonist might
be due to the several possible reasons such as: (a) down-regulation
of anti-inflammatory cytokine IL-10 and increased production
of inflammatory cytokine IL-12 and IFN-γ (32, 33); (b) down-
regulation of TNFR-2, which is known to regulate the proliferation
of oligodendrocytes and damage repair (34); (c) possibility of
reduced or non-permeability of the BBBs to TNFα blockers which
would prevents their direct action through these molecules could
still enhance the disease by increasing auto-reactive T cells in the
peripheral tissues, which can migrate into the CNS and damage
the tissues (35); (d) unmasking of latent infection, which is critical
for inducing the autoimmune demyelination reaction (36). Anti-
TNFα therapy has also been used to control other autoimmune
diseases such as RA. However, keeping in mind the possibility of
demyelination of the central and peripheral neuronal tissues by
such therapy, caution must be exercised, and careful monitoring
of any pre-existing neuronal disease or its development following
treatment with TNFα antagonists would be prudent.
Fas–FasL
Fas ligand (FasL, also known asCD95L, TNFSF6) is a type II trans-
membrane protein expressed on a variety of cells, includingCD8+
T cells and oligodendrocytes. It binds to the Fas receptor (Fas, also
known as CD95, TNFRSF6, apoptosis antigen 1) and the decoy
receptor 3 (DcR3). FasL–Fas interactions lead to the formation of a
DISC in the Fas-expressing cells, leading to induction of apoptosis.
The interaction of Fas with FasL on CNS infiltrating cells or
activated CNS-resident cells (microglia, astrocytes, and neurons)
also leads to the induction of apoptosis. FasL–Fas interactions play
a very important role in immune cell homeostasis, and its dysregu-
lation leads to various autoimmune diseases. Mice with autosomal
recessive mutations in Fas (lymphoproliferative, lprmice; lack Fas
expression) and FasL (generalized lymphoproliferative disease, gld
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mice; lack FasL expression) genes develop a spontaneous autoim-
mune syndrome; produce autoantibodies and accumulate a large
number of CD4 CD8  T cells in the secondary lymphoid tissues,
leading to the progressive development of lymphadenopathy and
splenomegaly (37, 38). Fas and FasL-deficient mice are resistant
to MOG-induced EAE, compared to wild-type mice (39, 40), and
intrathecal injection of recombinant FasL protein or neutralizing
with anti-FasL antibody suppresses acute EAE (41, 42). Adoptive
transfer of myelin basic protein (MBP)-specific FasL /  CD4
T cells in the wild-type host showed reduced EAE pathology
suggesting that FasL expression regulates the encephalitogenic
function of T cells (43). It would be interesting to study how these
auto-reactive CD4+ T cells cross BBB and cause neuronal tissue
damage. Determining the temporal and site-specific expression of
FasL in a variety of CNS-resident cells during ongoing neuroin-
flammation might provide valuable clues to address this question.
It has been also reported that Lpr mice on SJL/J background
are completely susceptible to the proteolipid protein (PLP139–51)-
induced EAE (40). This discrepancy might be due to the involve-
ment of other effector pathways mediated by various TNFRSF
members in the CNS.
Astrocytes constitutively express FasL, and they show both
positive and negative roles in the inflammation and the devel-
opment of EAE (44). Using targeted deletion of FasL, specifically
in astrocytes, Wang et al. showed that astrocytic FasL is required
for the elimination of auto-reactive T cells in the CNS (45).
Gamma-delta (γδ) T cells play a very important role in EAE
(46), and their deficiency results in chronic EAE (47). γδ T cells
were shown to regulate CNS inflammation and disease recovery
in a FasL–Fas-dependent manner by controlling the encephal-
itogenic CD4+ T cells (47). Collectively, these reports suggest
that Fas–FasL-mediated apoptosis acts as an intrinsic regulatory
mechanism to control neuroinflammation and development of
CNS autoimmunity.
BAFF-R–BAFF
The B-cell activating factor of the tumor necrosis factor family
(BAFF; also known as TNFSF13B, CD257, B lymphocyte stimu-
lator “BLys”), was originally described as a molecule secreted by
T cells and dendritic cells that provide maturation and survival
signals to peripheral B cells (48). Its expression was also reported
in other cell types such as macrophages, dendritic cells, and
neutrophils (49). BAFF transgenic mice have elevated numbers
of B cells and effector T cells, and show symptoms similar to
that seen in B-cell-mediated autoimmune diseases (50). Immature
B cells in the bone marrow express BAFF-receptor (BAFF-R),
and its expression is also up-regulated during the development
from transitional B-cell stage to mature B cell in the secondary
lymphoid organs (51, 52). BAFF also interacts with two more
known receptors expressed on the B cells; transmembrane activa-
tor calcium modulator and cyclophilin ligand interactor (TACI)
and B-cell maturation factor (BCMA) (53). TACI is known to
be expressed on marginal zone B cells, and BCMA on germinal
center B cells, plasma cells, and memory B cells (54). In addition
to BAFF, TACI andBCMAare also known to interact with another
TNFSF member known as APRIL (55, 56). Genetic deficiency
of BAFF-R in mice resulted in hyper-susceptibility to MOG35–55
peptide-induced EAE (57), suggesting that this receptor has a
regulatory function in EAE. It has been reported that defects in
the BAFF–BAFF-R signaling adversely influence the regulatory B-
cell (Breg) function, inducing early onset and severe pathology of
the disease (58). Huntington et al. showed that administration of
hBCMA–Fc fusion protein in C57BL/6 mice not only reduced the
B-cell numbers in peripheral blood, lymph nodes, and spleen, and
resulted in a reduced titer of MOG-specific antibody in the serum
but it also hampered the activation and differentiation of CD4+
T cells (59). It has also been reported that BAFF can enhance the
auto-reactive Th17 response, leading to increased progression of
EAE (60). Antibody-mediated blocking of BAFFwith anti-human
BLys attenuated the EAE in marmoset monkeys (61). Glatiramer
acetate (GA) is the approved frontline drug for the treatment
of EAE and MS, which acts on both innate as well as T and B
cells during EAE, and induces an anti-inflammatory microen-
vironment in the neuronal tissue (62–65). GA was also shown
to reduce BAFF mRNA expression in the brain, and decrease
the number of BAFF-R+ B cells, but not the TACI+ B cells in
the spleen of EAE mice (66). These reports clearly indicate that
BAFF–BAFF-R signaling contributes to the pathogenesis of EAE,
and its perturbation may provide a valuable therapeutics tool to
control CNS autoimmunity.
OX40–OX40L
The OX40 (also known as ACT35, CD134, TNFRSF4) is a type I
glycoprotein of ~50 kD, which is expressed on activated T cells,
such as Th1, Th2, Th17, Foxp3+ regulatory CD4+ T cell (Treg),
and CD8+ T cells (67). The OX40 ligand (OX40L also known
as gp34, CD252, TNFSF4) is a type II glycoprotein expressed
on APCs, such as dendritic cells, B cells, macrophages, and
endothelial cells (68). The interaction of OX40–OX40L provides
a costimulatory signal to T cells, which leads to their activation
and cytokine secretion (69). InhibitingOX40–OX40L interactions
protects from many inflammatory autoimmune diseases, includ-
ing EAE (70, 71). OX40–OX40L signaling in CD4+ T cells pro-
motes the expression of IL-12Rβ2 (72) while inhibits the expres-
sion of CTLA-4 (73), Foxp3 (74–76), and IL-10 (77). Selective
up-regulation of IL-12Rβ2 leads to the differentiation of Th1,
whereas loss of Foxp3, CTLA-4, and IL-10 inhibits the suppressive
function of Tregs. Thus, the loss of balance between pathogenic
and regulatory cells could promote autoimmune pathology. A
growing body of evidences suggests that OX40–OX40L interac-
tions regulate the differentiation of CD4+ T-cell subsets, and
deficiency of OX40 impairs Treg development (78). This might
be because the reverse signaling through OX40L in APCs leads to
the production of cytokines IL-6 and IL-12, which regulates the
differentiation of effector CD4+ T cells (68). It has been shown
that OX40L–OX40 signaling inhibits Foxp3 expression (75, 79),
and acts as a strong differentiating factor for Th9 in airway inflam-
mation (80). These studies suggest that OX40–OX40L signaling
could promote inflammatory responses, in addition to suppress-
ing anti-inflammatory responses in CD4+ T cells (68, 78). All
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these observations suggest that functional plasticity of the CD4+
T-cell subsets is also controlled by OX40L–OX40 interactions.
OX40–OX40L interactions in CD28-deficient mice initially
led to the identification of OX40–OX40L signaling as being
costimulatory in EAE, and blocking these interaction-protected
mice from EAE (71). In the rat EAE model, pathogenic OX40+
CD4+ T cells were found in CNS lesions, and neutralization of
OX40 by anti-OX40 antibody ameliorated the EAE (81). Targeting
OX40–OX40L interaction with an OX40–Ig fusion protein at the
onset of EAE greatly reduced the severity of the disease (82).
Brain endothelial cells are the central component of the BBB and
are known to express OX40L, which recruit OX40+ auto-reactive
T cells into the CNS (82). OX40 treatment of human umbilical
cord endothelial cells (HUVECs) lead to the up-regulation of
CCL5, suggesting that this signaling also modulates endothelial
cells to attract a selective population of immune cells at the BBB
(83). It would be interesting to study whether OX40 signaling
affects the expression of cell adhesion molecules, chemokines,
and integrins in the brain endothelial cells. Blocking OX40L by
anti-OX40L antibody reduces the infiltration of OX40+ myelin-
specific T cells in the spinal cord without affecting the priming of
the myelin-specific CD4+ T cells in the draining lymph nodes in
active as well as passive EAE (84). Therefore, OX40–OX40L not
only controls the activation and differentiation of CD4+ T cells,
but also potentiates their migration into the CNS. Together, these
reports indicate that OX40–OX40L supports the development of
neuroinflammation and CNS autoimmunity.
4-1BB (CD137) – 4-1BBL (CD137L)
4-1BB (TNFRSF9) is expressed on activated CD4+ T cells (Th1,
Th2, and Treg), CD8+ T cells, B cells, dendritic cells, NK cells,
NKT cells, and mast cells, whereas its ligand, 4-1BBL, is expressed
on activated APCs (macrophages, B cells, and dendritic cells),
CD4+ and CD8+ T cells, NK cells, mast cells, and smooth muscle
cells (85). Under inflammatory condition, neurons are also known
to express 4-1BBL (3). B7-deficient APCs deliver the costim-
ulatory signal to CD4+ T cells through 4-1BBL in a TRAF2-
dependent manner (86). It has been reported that stimulation
of human CD8+ T cells with 4-1BBL leads to the production of
effector molecules such as perforin and granzyme (3). Antibody
treatment with agonist anti-4-1BB (2A) in induced EAE resulted
in milder disease, but failed to control the development of passive
EAE by adoptive transfer of MOG35–55-specific CD4+ T cells
(87). Anti-4-1BB (2A) treatment induced IFN-γ and granulo-
cyte–macrophage colony-stimulating factor (GM-CSF) secretion
by MOG35–55-specific CD4+ T cells, leading to differentiation of
inflammatory Th1 (87). It has been suggested that targeting 4-1BB
or 4-1BB ligand could lead to the induction of unresponsiveness in
the CD4+ T cells during EAE (88, 89). 4-1BBL /  mice showed
reduced expression of vascular cell adhesionmolecule-1 (VCAM-
1) on spinal cord endothelial vessels, which play an important role
in the migration of immune cells in the inflamed CNS (89). 4-
1BBL downstream signaling induced the production of reactive
oxygen species (ROS) in microglia, leading to apoptosis of oligo-
dendrocytes in the EAE (85). Therefore, these studies indicate that
4-1BB–4-1BBL interactions not only promote the activation of T
cells, but also control the migration of myelin-specific CD4+ T
cells in the CNS. Furthermore, 4-1BBL signaling has a destructive
role in the inflamed CNS during EAE.
GITR–GITRL
Glucocorticoid-induced TNFR family-related gene (also known
as CD357, TNFRSF18) is expressed at the low levels in resting
mouse and human T cells, but is up-regulated on activated CD4+
and CD8+ T cells. GITR is constitutively expressed on Tregs
(90, 91). GITR–GITRL interactions inhibit the suppressive func-
tion of CD4+CD25+ Tregs and therefore, blocking these inter-
actions breaks the peripheral immune tolerance (92). GITRL is
expressed at the low levels on B cells, macrophages, bonemarrow-
derived dendritic cells, and endothelial cells (3). GITRL can act
as a costimulatory signal to CD4+CD25  and CD4+CD25+ T
cells (93), and to CD8+ T cells in the presence of suboptimal
concentrations of anti-CD3", in the absence of CD28-mediated
signaling (94). In addition, signaling through GITR stimulates the
production of cytokines such as IFN-γ, IL-2, IL-4, and IL-10 in
CD4+ T cells (95).
Regulatory B cells are known to produce anti-inflammatory
cytokine IL-10 (96) and suppress CNS autoimmunity (97).
Transgenic mice constitutively expressing GITRL on B cells
(GITRL+ B cells) showed a significantly higher numbers of
peripheral Tregs, suggesting that GITRL+ B cells might play a
role in the homeostasis of Tregs (99). Animals that received, B
cells pre-treated with anti-mouse GITRL antibody showed sig-
nificantly decreased Tregs induction and severe EAE, suggesting
that GITRL+ B cells support the proliferation and homeostasis of
Tregs (100). Treatment with Rituximab, a monoclonal antibody
that depletes B cells, including Bregs, leads to severe exacerbation
of human ulcerative colitis, suggesting that Bregs play an impor-
tant role in controlling CNS autoimmunity (98). A peripheral
increase in Treg frequency can inhibit the proliferation of myelin-
specific effector CD4+ T-cell subsets in the secondary lymphoid
organs, and can therefore control CNS autoimmunity. This clearly
indicates that B cells, through the expression of GITRL, pro-
mote and maintain the expansion of Tregs and contribute to the
maintenance of immune tolerance.
DR4/5–TRAIL
TNF-related apoptosis-inducing ligand (also known as CD253,
TNFSF10) is a type II membrane protein that binds to two death
receptors, DR4 (TRAIL-RI) and DR5 (TRAIL-RII). These recep-
tors are known to induce apoptosis in various cell types in a
caspase-dependent manner. Both DR4 and DR5 are known to
be expressed in humans, whereas mice express only DR5 (101).
TRAIL also binds to the decoy receptors, DcR1 (lack cytoplas-
mic domain) and DcR2 (truncated DD). Rather than inducing
apoptosis, binding to these receptors induces NFκB activation.
TRAIL receptors are expressed in neurons and oligodendrocytes,
but TRAIL is completely undetected in a healthy CNS. Signal-
ing from TRAIL–DR4/5 is implicated in the pathogenesis of
MS and EAE (101). TRAIL is generally found on infiltrating
Frontiers in Immunology | www.frontiersin.org July 2015 | Volume 6 | Article 3647
Sonar and Lal TNF superfamily in autoimmunity
immune cells and activated microglia in the MS lesions. The
DR4/DR5–TRAIL interaction seems to induce oligodendrocyte
and neuronal death during ongoing EAE. TRAIL-induced apop-
tosis of neurons and oligodendrocytes contribute to the devel-
opment of brain inflammation. Blocking brain-specific TRAIL
leads to a reduction in the severity of EAE. Similarly, thera-
peutic treatment with soluble TRAIL delays the onset of the
disease and reduces its severity (102). TRAIL is also reported
to inhibit Th1 response and promote the suppressive function
of Tregs (103). Genetically modified dendritic cells (ES-DCs),
which can simultaneously present MOG peptides in association
with MHC-II and express TRAIL, cause a reduction in the sever-
ity of EAE induced by both MOG35–55 and MBP (104, 105).
One of the mechanisms through which these ES-DCs controls
EAE is by promoting the proliferation of CD4+CD25+ Tregs,
which suppress myelin-specific effector CD4+ T-cell responses.
It might be possible that TRAIL signaling has a dual role;
it may promote suppressive phenotype in the secondary lym-
phoid organs, whereas in local inflamed CNS, it contributes to
tissue damage. Therefore, delineating the role of TRAIL sig-
naling in a spatio-temporal manner during the neuroinflam-
matory events might help in understanding the complexity of
CNS autoimmunity. Osteoprotegerin (OPG), a secreted protein
under physiological conditions, shows a lower binding affin-
ity for TRAIL (106); however, its role in CNS inflammation
and autoimmunity is not well studied. All these studies sug-
gest that, the apoptosis-inducing property of TRAIL in inflamed
CNS contributes to the development of inflammation and CNS
autoimmunity.
TWEAK–Fn14
TNF-like weak inducer of apoptosis (TWEAK; TNFSF12) is a
pro-inflammatory and pro-angiogenic cytokine synthesized as a
type II transmembrane protein. However, it can be cleaved to
give rise to soluble cytokine (107). Both membrane-bound and
soluble TWEAK bind to the only known receptor, fibroblast
growth factor-inducible 14 (Fn14; also known as TNFRSF12A).
TWEAK is expressed on monocytes, microglia, and astrocytes
in the healthy CNS. Its expression goes up during CNS inflam-
mation. Fn14 is also expressed on CNS-resident cells such as
brain endothelial cells, astrocytes, and neurons (108, 109). Over-
expression of soluble TWEAK by injecting TWEAK-encoding
recombinant plasmid (110), or in TWEAK transgenic animals
resulted in increased severity of EAE (109). These studies indicate
that local expression of TWEAK and Fn14 in the CNS could
be a critical contributing factor to the pathology of neuroin-
flammation. One of the mechanisms by which TWEAK elevates
CNS inflammation is by inducing CCL2 secretion from brain
endothelial cells and astrocytes. CCL2 is a potent activator of
neuroinflammation, and plays an important role in the pathogen-
esis of EAE and MS (111, 112). TWEAK–Fn14 signaling in BBB
endothelial cells compromises its barrier property in the mouse
models of cerebral ischemia. Therefore, it is possible that during
neuroinflammation such interactions can affect the BBB, allowing
the myelin-specific cells and soluble mediators to enter into the
CNS parenchyma (113, 114).
TWEAK–Fn14 binding does not induce ligand-activated
kinase signaling due to lack of cytoplasmic DD, but it triggers the
engagement of the TRAF, an adaptor protein that activates the
ERK1/2, PI3K/Akt, and NF-κB signaling pathways. Membrane-
bound TWEAK is a more powerful inducer of the classical NF-
κB signaling pathway than its soluble forms (115). It has been
shown that inhibition of TWEAK–Fn14 signaling decreases the
severity of EAE (110, 116) and CIA (117). Neutralization of
TWEAK after the priming phase with monoclonal antibody con-
trols immune cell infiltration into the neuronal tissues and reduce
the pathology of EAE (116). An immunotherapeutic fusion pro-
tein, Fn14–TRAIL consists of a portion of Fn14 receptor fused
with the TRAIL ligand, which blocks the function of TWEAK.
In vivo expression of this soluble functional chimera was shown
to control the EAE (118). A functional analysis of T-cell response
in these mice showed decreased effector Th1 and Th17 responses,
and increased number of suppressive Tregs, suggesting that the
balance was shifted more toward immune tolerance, which con-
trols the EAE (119). These studies suggest that TWEAK is a
very good therapeutic target to control neuroinflammation and
autoimmunity. Currently, several TWEAK-targeting therapeutic
agents are in clinical trials for autoimmunity and cancer (107).
CD70–CD27
The CD70 (CD27L, also known as TNFSF7) is a homotrimeric
type II transmembrane glycoprotein, and known to express on B
cells, T cells, mast cells, NK cells, and activated dendritic cells. It
is also expressed on epithelial cells in the thymic medulla. CD70
mainly resides in the endosomal compartment. Its expression is
activation-dependent, and controlled by the master transcription
regulator of MHC class II gene, CIITA. CD70 binds to its receptor
CD27 (TNFRSF7) expressed on CD4+ and CD8+ T cells, and
provides a costimulatory signal, which leads to the proliferation
and survival of activated B and T cells. The CD27–CD70 interac-
tion also controls effector and memory responses, and prevents
the induction of tolerance (120). Treatment of animals with anti-
CD70 antibody suppresses the EAE, possibly by inhibiting the
TNF-α production by draining lymph node cells (121). CD70-
transgenic mice showed increased numbers of IFN-γ-producing
CD4+ and CD8+ T cells, suggesting that CD70–CD27 signal-
ing controls Th1 (120). It has been reported that CD27+ γδ
T cells express high levels of IFN-γ and lower levels of IL-17,
whereas CD27  γδ T cells express lower levels of IFN-γ and
high levels of IL-17, suggesting that CD27 essentially controls
the differentiation of γδ T cells, which gives rise to two differ-
ent effector subsets of γδ T cells (46, 122, 123). The deficiency
of CD27 and CD70 in animals leads to significantly increased
EAE. In contrast, CD70-Tg mice showed reduced EAE pathology
(124, 125). Furthermore, Coquet el al. reported increased Th17
response in CD27 /  and CD70 / , and reduced Th17 in CD70-
Tg mice (124). They concluded that this increased Th17 differen-
tiation in CD27 /  and CD70 /  animals were due to increased
phosphorylation of the JNK and epigenetic modification at IL-
17 locus, suggesting that CD70–CD27 signaling directly controls
the Th17 response in CD4+ T cells (124). Interestingly, anti-
CD70 antibody-mediated blocking of CD70 prevented EAE in
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SJL/J mice (121), and over-expression of CD70 on the B cells
enhanced EAE (126). This is in contrast to what is reported
by Coquet et al. (124). These discrepancies might be due to
the differences in the mouse strains used or in the cell types
where CD70-Tg was over expressed, since over-expression of
CD70 in B cells leads to hyper-activation of T cells and a grad-
ual loss of B cells (127). CD70 signaling affects the expression
of IL-17F and CCR6 but not other Th17-associated molecules
such as RORs, BATF, and IL-23R (124), suggesting that target-
ing CD27 may be beneficial in controlling effector CD4+ T-cell
differentiation and its migration into the inflamed tissues during
autoimmunity.
LTbR–LTa
Lymphotoxin alpha (also known as TNFSF1) exists as a secreted
homotrimeric molecule produced by lymphocytes. LTα also
forms a membrane-anchored heterotrimer with LTβ (Figure 1).
LTα homotrimer (LTα3) interacts with TNFR-1, TNFR-2, and
herpes virus entry mediator (HEVM), whereas the heterotrimer
molecule (LTα1β2) interacts with the LTβR (also known as
TNFRSF3) (Figure 1). LTβR is expressed on most cell types,
including epithelial cells, endothelial cells, and cells of themyeloid
lineages, but not on B and T lymphocytes. LT levels were known
to increase in the CNS before the onset of clinical signs of
EAE, suggesting a role in the pathogenesis of CNS inflammation.
Treatment with LTβR–Ig fusion protein alters the localization of
leukocytic infiltration into the CNS and controls the EAE (128).
LTα /  mice have developmental defects in the lymph node
formation, and lack Peyer’s patches (129). LTα /  mice show
reduced demyelination and CNS inflammation in MOG35–55-
induced EAE. However, adoptive transfer of MOG35–55-specific
wild-type T cells induces EAE (130). This indicates that LT–LTβR
signaling mainly regulates the priming phase of myelin-specific
T-cell activation and development, but not the actual homing
of these auto-reactive cells into the inflamed CNS. In contrast,
LTβ / mice developMOG35–55-inducedEAE, but to a somewhat
lesser extent as compared to wild-type animals. These results
suggest that LTα plays a very important role in the development
of EAE (130). LIGHT (CD258, also known as TNFSF14) is a
potent, CD28-independent costimulatory molecule expressed on
T cells that are involved in initial T-cell priming and expansion.
LIGHT can interact with both LTβR and HEVM. Interaction of
LIGHT with HVEM has a costimulatory function, whereas its
interaction with LTβR induces apoptosis. LIGHT-deficient mice
develop more severe MOG35–55-induced EAE due to intensive
activation of microglia/macrophages and increased frequency of
apoptotic cells within the CNS parenchyma, as compared to
wild-type animals (131). Expression of LIGHT on CNS-resident
cells rather than myelin-specific CD4+ T cells is the most cru-
cial factor in the pathogenesis of EAE. This also suggests that
LIGHT expression plays an important role in controlling the acti-
vated microglia/macrophages during CNS inflammation. There-
fore, selective targeting of LIGHT–HVEM signaling may provide
protection against neuroinflammation and CNS autoimmunity.
However, the involvement of LIGHT–HVEM interactions with
other CNS-resident and infiltrating cells is not well characterized.
It would be interesting to study these interactions in different
stages of neuroinflammation.
CD40–CD40L
The CD40 ligand (CD154, also known as TNFSF5) is expressed
on activated T cells, and binds to its cognate receptor CD40
(TNFRSF5) on APCs. CD40L–CD40 interactions lead to the
activation of B cells, their differentiation into plasma cells, and
immunoglobulin class switching. The CD40L–CD40 interactions
play a very important role in many autoimmune diseases. The
disruption or blocking of this interaction inhibits clinical man-
ifestation and ameliorates the EAE in mice and monkeys (132,
133). In the CNS, various cells, including astrocytes and glial cells
express CD40, and expression of this molecule is required for
the development of EAE (133, 134). It has been reported that
blocking of CD40L–CD40 interaction controls the development
of EAE (135, 136). Treatment of animals with remitting EAE in
this manner not only controls the EAE, but also inhibits the long-
term delayed type hypersensitivity (DTH) response (137). One
study has reported that mast cells and astrocytes are localized
together in the inflamed CNS, and they have potential to interact
with each other via CD40L on mast cells and CD40 on astrocytes
(134). In vitro studies have shown that this interaction activates
astrocytes leading to the secretion of cytokines. These cytokines
act in an autocrine manner, and potentiate multiple signaling
via the JAK-STAT-1 (Tyr701) pathway in the astrocytes (134).
Therefore, a contributing signaling event that can enhance the
function of infiltrating effector immune cells as well as CNS-
resident cells may also promote axonal damage. These reports
suggest that CD40–CD40L costimulatory signaling contributes to
neuroinflammation and CNS autoimmunity.
Future Perspective
The growing body of evidence demonstrated that TNF–TNFR
interactions are involved in the pathogenesis of EAE and MS.
These interactions control the disease outcome by fine-tuning
the peripheral immune response as well as interactions between
CNS-resident cells and effector immune cells in the CNS. Several
reports suggest that the TNFSF–TNFRSF pairs that signal the
promotion of inflammation are OX-40–OX40L, sTNFα–TNFR-
1, CD27–CD70, 4-1BB–4-1BBL, Fn14–TWEAK, CD40–CD40L,
andLT-α/LTβ–LTβR;whereas the ones that showaprotective role
are tmTNFα–TNFR-2, DR4/DR5–TRAIL, and HVEM–LIGHT.
Conflicting results have been reported in the literature about
some of the interactions and their importance in CNS autoim-
munity. These discrepancies in the results reported by different
investigators may be due to the differences in the animal models
used or immunization strategies employed to induce the EAE.
Furthermore, cross-talks between the signaling induced by vari-
ous TNFSF–TNFRSF may also contribute to the pathogenesis of
disease. Keeping in mind that the combination therapy is cen-
tral to immunotherapeutic approaches, understanding how and
when to block TNFSF–TNFRSF interactions, individually or in
combination with other targets, depends on our in-depth knowl-
edge of their expression patterns and molecular mechanisms.
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Since, there are several TNF superfamily members that have the
ability to influence neuroinflammation one way or another, reach-
ing a decision about targeting one ormore receptor–ligand pairs at
a given time for clinical application requires further investigation.
A better understanding of their expression profile, and kinetics
of expression, and interactions between TNF ligands and their
TNFRs on various CNS residents and infiltrating immune cells at
different stages of the diseasewould help to design better strategies
to control neuroinflammation and CNS autoimmunity.
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